Merck Vet Manual gets new editor-in-chief
Laurie Hess, DVM, has joined the Merck Manuals team as Editor-in-Chief of the Merck Veterinary Manual and Director, Scientific Affairs.
If you are not happy with the results below please do another search
Laurie Hess, DVM, has joined the Merck Manuals team as Editor-in-Chief of the Merck Veterinary Manual and Director, Scientific Affairs.
Today the company said its experimental drug helped reduce symptoms of major depressive disorder (MDD) and insomnia in a late-stage trial when given along with commonly used antipsychotic treatments.
Today the company announced a deal worth $3 billion to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the pharma’s return to the ophthalmology space after nearly a decade.
The company announced its plans to revise its financial statements in March, citing “material weakness in its internal control over financial reporting”.
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.
Consumers generally are not fans of risk. But when consumers become patients, the game changes.
Johnson & Johnson is continuing its buying activity in the skin disease space, announcing Tuesday plans to purchase Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, and its bispecific antibody NM26 for $1.25 billion in cash.
Japanese conglomerate Asahi Kasei announced Tuesday that it has made a SEK 11.1 billion ($1.1 billion) offer to purchase the Swedish pharmaceutical company Calliditas Therapeutics, with its board of directors recommending that the offer be accepted.
Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the weekend.
AstraZeneca and Daiichi Sankyo on Monday revealed additional data from the Phase III TROPION-Lung01 study, showing that their investigational antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) failed to significantly improve overall survival in non-small cell lung cancer patients.